CNSP_RF1.txt
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SCHEDULE 13G Under the Securities Exchange Act of 1934 CNS Pharmaceuticals Inc
--------------------------------------- (Name of Issuer) Common Stock
------------ (Title of Class of Securities) 18978H300 --------- (CUSIP Number)
June 17th, 2024 ----------------- (Date of Event which Requires Filing
this Statement)Check the appropriate box to designate the rule pursuant to
which the Scheduleis filed:[ ] Rule 13d-1(b)[X] Rule 13d-1(c)[ ] Rule
13d-1(d)*The remainder of this cover page shall be filled out for a reporting
person'sinitial filing on this form with respect to the subject class of
securities, andfor any subsequent amendment containing information which would
alter thedisclosures provided in prior cover page.The information required in
the remainder of this cover page shall not be deemedto be "filed" for the
purpose of Section 18 of the Securities Exchange Act of1934 ("Act") or
otherwise subject to the liabilities of that section of the Actbut shall be
subject to all other provisions of the Act (however, see theNotes). Page 1 of
5SEC 1745 (10-88)
SCHEDULE 13GCUSIP NO. 18978H300 ---------- -------------------------------------
--1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE
PERSON Robert Forster- -----------------------------2. CHECK THE APPROPRIATE
BOX IF A MEMBER OF A GROUP* (a) / /. (b) / /.- ------------------------------3.
SEC USE ONLY- ------------------------------4. CITIZENSHIP OR PLACE OF
ORGANIZATION United States- ----------------------------- 5. SOLE VOTING POWER
0 NUMBER OF -------- ------------- SHARES 6. SHARED VOTING POWER BENEFICIALLY
0 OWNED BY -------- -------------- EACH 7. SOLE DISPOSITIVE POWER REPORTING 0
PERSON -------- --------------- WITH 8. SHARED DISPOSITIVE POWER 0-
-------------------------------- --------9. AGGREGATE AMOUNT BENEFICIALLY
OWNED BY EACH REPORTING PERSON 0- ------------------------------------------10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / /.-
---------------------------------------11. PERCENT OF CLASS REPRESENTED BY
AMOUNT IN ROW 9 0%- ----------------------------------12. TYPE OF REPORTING
PERSON* individual- ------------------------------------ *SEE INSTRUCTION
BEFORE FILLING OUT! Page 2 of 5
STATEMENT ON SCHEDULE 13GItem 1(a). Name of Issuer: --------------- CNS
Pharmaceuticals IncItem 1(b). Address of Issuer's Principal Executive Offices:
------------------------------------------------ 2100 West Loop South, Suite
900 Houston, Texas 77027Item 2(a). Names of Person Filing: -------------------
---- Robert ForsterItem 2(b). Address of Principal Business Office or, if
none, Residence: ------------------------------------------------------------
54 Deepdale Dr, Great Neck, NY 11021Item 2(c). Citizenship: ------------
United StatesItem 2(d). Title of Class of Securities: --------------------------
--- Common StockItem 2(e). CUSIP Number: ------------- 18978H300Item 3. If
this statement is filed pursuant to Rules 13d-1(b), or -------------------------
-------------------------------- 13d-2(b), check whether the person filing is
a: ----------------------------------------------- (a) / / Broker or Dealer
registered under Section 15 of the Act (b) / / Bank as defined in section
3(a)(6) of the Act (c) / / Insurance Company as defined in section 3(a)(19) of
the Act (d) / / Investment Company registered under section 8 of the
Investment Company Act (e) / / Investment Advisor registered under section 203
of the Investment Advisers Act (f) / / Employee Benefit Plan, Pension Fund
which is subject to the provisions of the Employee Retirement Income Security
Act of 1974 or Endowment Fund; see Sec.240.13d-1(b)(ii)(F) (Note: See Item 7)
(g) / / Parent Holding Company, in accordance with Sec.240.13d-1(b)(ii)(G).
(Note: See Item 7) (h) / / Group, in accordance with Sec.240.13d-1(b)(ii)(H).
Page 3 of 5
Item 4. Ownership: ---------- (a) Amount Beneficially Owned: 0 as of 17th June
2024 ------ (b) Percent of Class: 0% ----- (c) Number of shares as to which
such person has: (i) sole power to vote or to direct the vote: 0 ------ (ii)
shared power to vote or to direct the vote: 0 ----- (iii) sole power to
dispose or to direct the disposition of: 0 ------ (iv) shared power to dispose
or to direct the disposition of: 0 -----Item 5. Ownership of Five Percent or
Less of a Class: --------------------------------------------- yesItem 6.
Ownership of More than 5 Percent on Behalf of Another Person: ------------------
------------------------------------------- Not ApplicableItem 7.
Identification and Classification of the Subsidiary Which ----------------------
----------------------------------- Acquired the Security Being Reported on By
the Parent Holding -------------------------------------------------------------
Company: -------- Not ApplicableItem 8. Identification and Classification of
Members of the Group: ----------------------------------------------------------
Not ApplicableItem 9. Notice of Dissolution of Group: -------------------------
------ Not ApplicableItem 10. Certification: -------------- By signing below,
I certify that, to the best of my knowledge and belief, the securities
referred to above were acquired in the ordinary course of business and were
not acquired for the purpose of and do not have the effect of changing or
influencing the control of the issuer of such securities and were not acquired
in connection with or as a participant in any transaction having such purposes
or effect. Page 4 of 5